Krystal Biotech (KRYS) Net Income towards Common Stockholders (2016 - 2026)

Krystal Biotech has reported Net Income towards Common Stockholders for 11 years, with the latest figure at $54.8 million in Q2 2026.

• Net Income towards Common Stockholders for Q2 2026 came in at $54.8 million, up 42.87% year-over-year; the trailing twelve-month figure through Jun 2026 was $241.5 million (up 64.58% YoY), and the FY2025 annual result was $204.8 million, up 129.74% from the prior year.
• Net Income towards Common Stockholders fell to $54.8 million in Q2 2026, from $55.9 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at $80.7 million in Q3 2023 and troughed at -$114.3 million in Q1 2023.
• A 5-year average of $5.8 million and a median of $21.4 million in 2024 frame the typical range for Net Income towards Common Stockholders.
• The widest annual swing landed in 2022, when Net Income towards Common Stockholders tumbled 106.66%; it then soared 3730.15% in 2025.
• A 5-year view of Net Income towards Common Stockholders shows it stood at -$34.0 million in 2022, then soared by 125.55% to $8.7 million in 2023, then soared by 423.62% to $45.5 million in 2024, then rose by 12.91% to $51.4 million in 2025, then grew by 6.57% to $54.8 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were $54.8 million in Q2 2026, $55.9 million in Q1 2026, and $51.4 million in Q4 2025.